



Attorney Docket No. 5146

FFD  
PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rudolph, et al.

Serial No.: 10/719,485

Title: Anilinopyrazole Derivatives Useful for the Treatment of Diabetes

**MAIL STOP PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

### **TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449.

### **IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

### **FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
\_\_\_\_\_  
Susan M. Pellegrino  
Reg. No.: 48,972  
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-6450  
Facsimile: (203) 812-6459

## INFORMATION DISCLOSURE CITATION

Applicant(s)  
Rudolph, et al.

JUN 10 2004

## U.S. PATENT DOCUMENTS

*		DOCUMENT NO.								DATE (MM/DD/YY)	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	U1	5	9	9	8	4	2	4	12/07/99					
	U2	5	9	1	6	9	0	8	06/29/99					
	U3	5	9	4	2	5	2	0	08/24/99					
	U4	3	7	9	0	5	7	6	02/05/74					

## FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.								DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
		YES	NO												
	F1	9	6	1	4	8	4	3	23/05/96	WO					
	F2	1	1	4	3	5	1	5	14/02/63	DE					
	F3	9	7	0	8	1	4	9	06/03/97	WO					
	F4	9	3	1	9	0	5	4	30/09/93	WO					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Menzel, et al., "Synthesen und Reaktionen neuer ortho-kondensierter Pyrazoloverbindungen," <i>Angew. Chem.</i> , <b>74</b> (21), 839-847 (1962).
R2	Crenshaw, et al., "Interferon Inducing Activities of Derivatives of 1,3-Dimethyl-4-(3-dimethylaminopropylamino)-1H-pyrazolo[3,4- <i>b</i> ]quinoline and Related Compounds," <i>J. Med. Chem.</i> , <b>19</b> (2), 262-275 (1976).
R3	Catarzi, et al., "Tricyclic Heteroaromatic Systems. Synthesis and A <sub>1</sub> and A <sub>2a</sub> Adenosine Binding Activities of Some 1-Aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3- <i>c</i> ]pyrazol-4-ones, 1-Aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4- <i>b</i> ]quinolin-4-ones, and 1-Aryl-1H-imidazo[4,5- <i>b</i> ]quinoxalines," <i>J. Med. Chem.</i> , <b>38</b> , 1330-1336 (1995).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.